Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation
Brief Summary: The purpose of this study is to provide information on the risks and benefits of routine blood pressure lowering (regardless of blood pressure level), and intensive lowering of blood glucose levels, in patients with Type 2 diabetes at high risk of cardiovascular events. The major outcomes of the study will be cardiovascular events (heart attack, stroke or dying as a result of cardiovascular disease), as well as new or worsening diabetic eye and kidney disease.


Options:
A: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
B: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Intervention Type: DRUG; Name: Insulin Glargine (HOE901)/NPH Insulin; Assigned to Arm(s): 1, 2
D: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 low dose, Drug: Placebo BI 10773 high dose | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 high dose, Drug: Placebo BI 10773 low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo BI 10773 high dose, Drug: Placebo BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773 low dose; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773 high dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): BI 10773 low dose

Answer: B